This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Fresenius Medical Care AG & Co. KGaA (0H9X) Receives a Hold from Barclays
Barclays analyst Hassan Al-Wakeel maintained a Hold rating on Fresenius Medical Care AG & Co. KGaA today and set a price target of €46.50.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Al-Wakeel is ranked #10100 out of 12161 analysts.
In a report released yesterday, Deutsche Bank also maintained a Hold rating on the stock with a €42.00 price target.
0H9X market cap is currently €11.24B and has a P/E ratio of 12.14.
Read More on GB:0H9X:
Disclaimer & DisclosureReport an Issue
- Fresenius Medical price target lowered to EUR 42 from EUR 44 at Deutsche Bank
- Fresenius Medical price target lowered to EUR 34 from EUR 36 at Morgan Stanley
- Fresenius Medical reports Q4 EPS ex-items EUR1.44 vs. EUR0.91 last year
- Fresenius Medical sees 2026 revenue growth flat vs. EUR19.63B in 2025
- Sell Rating on Fresenius Medical Care Amid Unsustainable Earnings Quality and Structural Headwinds
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
